Navigation Links
Adeona Reports Third Quarter 2011 Financial Results
Date:11/14/2011

ts presented in April 2011 from the clinical study evaluating our medical food, reaZin™, an apparent cognitive benefit was observed in older patients.
  • Preparations are underway to conduct a larger clinical study of AEN-100 (our zinc-based drug candidate) under an IND application in patients with mild to moderate Alzheimer's disease who are age 70 and older. It is anticipated that the clinical study will enroll just over 100 patients and that the evaluation period will be at least 12 months.

Product Development Programs

Reducing the Duration and Symptoms of the Common Cold

  • On November 4, 2011, we executed an agreement with F&F Foods of Chicago, Illinois, to provide commercial-scale manufacturing of wellZin.

  • On August 25, 2011, George A. Eby, a researcher who has conducted multiple clinical studies of zinc lozenges for the common cold, was appointed as a member of our Scientific Advisory Board.

Dietary Management of Zinc Deficiency Associated with Alzheimer's Disease

  • In April 2011, clinical study results were presented that demonstrated, on average, that the cognitive function of the placebo group, declined over six months in comparison to patients managed with reaZin, a medical food. The cognitive function trends favoring the patients managed with reaZin were observed in all three standardized cognitive tests utilized in our study and suggest that reaZin may provide an important benefit to the dietary management of zinc deficiency associated with Alzheimer's disease.

  • Based on the results of our clinical study, we are developing reaZin as a medical food for the dietary management of zinc deficiency associated with A
    '/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
2. Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting
3. Adeona Appoints Jeff Lucero Riley as Independent Chairman
4. Adeonas Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease is Hot Topic at 2011 California ALS Research Summit
5. Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
6. Adeona Appoints George A. Eby to Scientific Advisory Board
7. Adeona Reports Second Quarter 2011 Financial Results
8. Adeona to Host Second Quarter 2011 Investor Conference Call
9. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
10. Adeona Reports 1st Quarter 2011 Financial Results
11. Adeona to Host First Quarter 2011 Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic ... clinical trial of SG2000 in ovarian cancer.  The trial ... of the USA, and is now actively recruiting patients ... will evaluate the overall response rate of SG2000 in ...
... (NYSE: AZN ) today announced that ... extended the time to complete its review of ... (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO) (Logo: ... Prescription Drug User Fee Act (PDUFA) date from ...
Cached Medicine Technology:Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 2Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 3U.S. Food and Drug Administration Extends Review Timeline for BRILINTA (Ticagrelor) New Drug Application 2
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... 9, 2014 There has been a sharp increase ... Medical Center using MyChart, the online, interactive service that ... with their healthcare providers, schedule appointments, and renew prescriptions. ... actively using MyChart each year increased five-fold, ... more than 10-fold, according to a study by ...
(Date:7/9/2014)... around the world have been linked to an ... from the National Institute for Mathematical and Biological ... also contribute. , In a series of ... severe hemorrhage of internal organs in frogs, could ... if they are exposed to the virus every ...
(Date:7/9/2014)... a reputation for being highly toxic, but when used in ... found to offer potential health benefits in a range of ... new compound (AP39), designed and made at the University of ... delivery of very small amounts of the substance to the ... Exeter have already found that the compound protects mitochondria ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2
... August 16, 2011 Seattle Children,s Research Institute ... million grant from the Bill & Melinda Gates ... respiratory support device, called Seattle Children,s Positive Airway ... affordable and simple Bubble Continuous Positive Airway Pressure ...
... Italy, August 16, 2011 Facial expressions convey strong ... interpret these cues is crucial in social interaction. This ... and neurological disorders, such as social anxiety or Korsakoff,s ... stress disorder (PTSD) is also characterized by changes in ...
... 16 (HealthDay News) -- Many women in the United States ... due to dangerous ingredients, a new study indicates. Pai ... which are banned in the United States because they increase ... U.S. Food and Drug Administration announced a recall of Pai ...
... exercise routine means being able to overcome the obstacles ... the confidence that you can do it, researchers report. ... abilities increase this "situation-specific self-confidence," a quality the researchers ... self-efficacy to every single health behavior you can think ...
... 15 (HealthDay News) -- You might want to take a ... researchers report that alcohol hinders the restorative functions of sleep. ... students, appear online and in the November print issue of ... Booze,s effect on sleep appears linked to a disruption ...
... , MONDAY, Aug. 15 (HealthDay News) -- ,Just 15 ... death by 14 percent and increase your life expectancy by three ... to do at least 150 minutes, or a total of 1.5 ... finds that doing even half that -- 15 minutes daily is ...
Cached Medicine News:Health News:Seattle Children's lands major funding with hopes of saving thousands of infant lives 2Health News:Seattle Children's lands major funding with hopes of saving thousands of infant lives 3Health News:Reduced recognition of fear and sadness in post-traumatic stress disorder 2Health News:U.S. Women Using Dangerous Weight-Loss Pill 2 Years After Recall 2Health News:Want to keep your exercise resolutions? New research offers pointers 2Health News:Want to keep your exercise resolutions? New research offers pointers 3Health News:More Evidence That Alcohol Hinders Good Sleep 2Health News:A Little Exercise Goes a Long Way to Cut Disease, Death Risk 2
... a two-level control compatible with popular ... Strips and Roche Micral test strips. ... turbidimetric immunoassays using AU Series, Bayer ... Cobas, Diasorin SPQ Test System, Dimension, ...
... the performance of Abuscreen ONLINE, AxSYM, EMIT, ... methods. This control meets current revised guidelines ... Health Services Administration (SAMSHA). Level 1 is ... analytes below screening cut-off levels (negative threshold ...
... 190 spectrophotometer is ideal for most life ... solutions, our patented* PathCheck sensor technology senses ... microplate well, and normalizes the absorbance value ... is within 5% of the value obtained ...
... This control is intended as a ... testing methods. A new feature is ... CRP. It is compatible with most ... ACS:180, Access, Dimension, Elecsys, Stratus and ...
Medicine Products: